Investigational drugs for allergic rhinitis

Expert Opinion on Investigational Drugs

Volumn 19, Issue 1, 2010, Pages 93-103

  Passalacqua, Giovanni ^a   Compalati, Enrico ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergen specific immunotherapy; Allergic rhinitis; Inflammation; Monoclonal antibodies.

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; AZELASTINE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CICLESONIDE; DECONGESTIVE AGENT; DESLORATADINE; EBASTINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GSK 1004723; GSK 256066; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE DERIVATIVE; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; OLOPATADINE; OMALIZUMAB; PLACEBO; RUPATADINE; STEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC REACTION; ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; LONG TERM CARE; PATHOGENESIS; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SUBLINGUAL IMMUNOTHERAPY; TH2 CELL; TREATMENT DURATION;

ADMINISTRATION, INTRANASAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; RHINITIS, ALLERGIC, SEASONAL;

EID: 72049098852     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903435647     Document Type: Review

References (94)

1. Bousquet J, Kalthaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2) LEN and AllerGen). Allergy 2008; 63(Suppl 86):8-160
2. Lai CK, Beasley R, Crane J, et al.; International Study of Asthma and Allergies in Childhood Phase Three Study Group. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009;64:476-483
3. Weinmayr G, Forastiere F, Weiland SK, et al.; ISAAC Phase Two Study Group. International variation in prevalence of rhinitis and its relationship with sensitisation to perennial and seasonal allergens. Eur Respir J 2008;32:1250-1261
4. Baiardini I, Braido F, Tarantini F, et al.; GA2LENARIA-suggested drugs forallergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy 2008;63:660-669
5. Schoenwetter WF, Dupclay L Jr, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004;20:305-317
6. Vandenplas O, D'Alpaos V, Van Brussel P. Rhinitis and its impact on work. Curr Opin Allergy Clin Immunol 2008;8:145-149
7. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381-387
8. Bousquet J, Annesi-Maesano I, Carat F, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005;35(6):728-732
9. Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372(9643):1049-1057
10. Wilson Am, O Byrne P. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116(5):338-344
11. J Bousquet, C Bachert, Gw Canonica, et al. The extended GA2LEN and World Allergy Organization Study Group Unmet needs in Severe Chronic Upper Airway Diseases (SCUAD). J Allergy Clin Immunol 2009. In press
12. Pawankar R, Yamagishi S, Takizawa R, Yagi T. Mast cell-IgE-and mast cell-structural cell interactions in allergic airway disease. Curr Drug Targets Inflamm Allergy 2003;2:303-312
13. Kelly M, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007;120(1):3-10
14. Ciprandi G, Vizzaccaro A, Cirillo I, et al. Nasal eosinophils display the best correlation with symptoms, pulmonary function and inflammation in allergic rhinitis. Int Arch Allergy Immunol 2005;136:266-272
15. Ciprandi G, Marseglia G, Klersey A, Tosca M. Relationships between allergic inflammation and nasal airflow in children with persistent allergic rhinitis due to mite sensitization. Allergy 2005;60(7):957-960 (Pubitemid 40813820)
16. Ciprandi G, Buscaglia S, Pesce GP. et al. Minimal persistent inflammation is present at mucosal level in asymptomatic rhinitic patients with allergy due to mites. J Allergy Clin Immunol 1995;96:971-979
17. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004;113(3):395-400
18. Romagnani S. Regulatory T cells: which role in the pathogenesis and treatment of allergic disorders? Allergy 2006;61:3-14
19. Annunziato F, Cosmi L, Liotta F, et al. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 2008;20(11):1361-1368
20. Bousquet J, Fokkens W, Burney P, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy 2008;63:842-853
21. Passalacqua G, Ciprandi G, Guerra L, et al. An update on the asthma-rhinitis link. Curr Opin Allergy Clin Immunol 2004;4:177-183
22. Braunstahl GJ. The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J Allergy Clin Immunol 2005;115:142-148
23. Cruz AA, Popov T, Pawankar R, et al.; ARIA Initiative Scientific Committee. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007;62(Suppl 84):1-41
24. Bousquet J. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy. Clin Exp Allergy 2005;35(6):723-727
25. Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2009;30:244-254
26. Craig TJ, McCann JL, Gurevich F, Davies MJ. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 2004;114(5 Suppl):S139-45
27. Gani F, Pozzi E, Crivellaro MA, et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy 2001;56:65-68
28. Custovic A, van Wjik G. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy 2005;60:1112-1115
29. Simons FER. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-2217
30. Weiner JM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials
31. Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000;55:16-33
32. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Bousquet J, Lockey R, Malling HJ, editors. Allergy 1998:53 (Suppl 72): 3-13
33. Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008;8(6):571-576
34. Passalacqua G, Durham SR; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-891
35. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-256
36. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-856
37. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101(2):206-211
38. Dent G. Ciclesonide. Curr Opin Investig Drugs 2002;3:78-83
39. Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled orticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther. 2006;28:319-331
40. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005;60:330-337
41. Schmidt BM, Timmer W, Georgens AC. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin Pharmacol 1999;39:1062-1069
42. Dhillon S, Wagstaff A. Ciclesonide nasal spray: in allergic rhinitis. Drugs 2008 68(6):875-883
43. Ahlstrom-Emanuelsson C, Andersson M, Persson C, et al. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy 2004;34:731-735
44. D. A. Atkinson, T. Uryniak, B. Simpson, L. O'Dowd. A comparison of rofleponide palmitate nasal spray (RPNS) with placebo and mometasone furoate nasal spray (MFNS) in adolescent and adult patients with seasonal (mountain cedar) allergic rhinitis (AR) [abstract]. J Allergy Clin Immunol 2004;113(2 Suppl 1):S175
45. Patel PS, Roland BF, Marple PJ, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 2007;137:918-924
46. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis J Allergy Clin Immunol 2001;108(4):530-536
47. Rimmer J, Peake HL, Santos CM, et al. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2007;37(1):8-14
48. Ahlström L, Emanuelsson C, Andersson M, et al. Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis. Respir Med 2007;101(6):1106-1112
49. Till SJ, Durham SR. Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008;21:59-70
50. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy 2008;38:1074-1088
51. Wilson DR, Torres L. Durham SR. Sublingual immunotherapy for allergic rhinitis Allergy 2005;60:3-8
52. Calamita Z, Saconato H, Bronhara Pelà A, et al. Efficacy of Sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 2006;61:1162-1172
53. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in children. Meta analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2006;97:141-148
54. Penagos M, Passalacqua G, Compalati E, et al. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17951626?ordinalpos=1&itool= EntrezSystem2.PEntrez.Pubmed.Pubmed-ResultsPanel. Pubmed-RVDocSumMetaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609
55. Di Rienzo V, Musarra A, Sambugaro R, et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560-564
56. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254-258
57. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61(2):185-190 (Pubitemid 43381828)
58. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117(4):802-809
59. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118(2):434-440
60. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120(6):1338-1345
61. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5 grass pollen subllingualimmunotherapy in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009. In press
62. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179-186
63. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-173
64. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105(46):17908-17912
65. Drachenberg KJ, Wheeler A, Stubner P, Horak F. A well tolerated grass pollen specific allergy vaccine containing a novel adjuvant MPL reduces allergy symptoms after only four preseasonal injections. Allergy 2001;56:498-505
66. Simons FE, Shikishima Y, Van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004;113:1144-1151
67. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113:235-241
68. Creticos PS, Schroeder JT, Hamilton RG, et al; Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-1455
69. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101(Suppl 2):14677-14682
70. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-960
71. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-613
72. Oldfield WL, Larchè M, Kay AB. A double blind placebo controlled study of short-peptides derived from Fel d 1 iN cat allergic subjects. Lancet 2002;360:47-53
73. Suwaki T, Agrawal DK, Townley RG. Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug. Int Immunopharmacol 2001;1:2163-2171
74. Washio Y, Ohashi Y, Tanaka A, et al. Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis. Acta Otolaryngol Suppl 1998;538:126-132
75. Furukido K, Takeno S, Ueda T, et al. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am J Rhinol 2002;16:329-336
76. Horiguchi T, Tachikawa S, Handa M, et al. Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness. J Asthma 2001;38:331-336
77. Yamada J, Hamuro J, Hatanaka H, et al. Alleviation of seasonal allergic symptoms with superfine beta-1,3-glucan: a randomized study, J Allergy Clin Immunol 2007;119: 1119-1126
78. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005;115:791-796
79. Prenner BM. Asthma 2008: targeting immunoglobulin E to achieve disease control. J Asthma 2008;45(6):429-436
80. Berger WE. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody. Allergy Asthma Proc 2006;2(Suppl 1):S29-32
81. Casale TB, Bernstein IL, Busse W, et al. Use of an antiIgE monoclonal antibody in ragweed induced allergic rhinitis. J Allergy Clin immunol 1997;100:110-121
82. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-167
83. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286:2956-2967
84. Adelroth E, Rak S, Haatela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-259
85. Cox L, Platts-Mills TA, Finegold I, et al.; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120(6):1373-1377
86. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-717
87. Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis-and eventually nasal polyps? Int Arch Allergy Immunol 2009;148(2):87-98
88. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004;59(9):973-979
89. Kopp MV, Hamelmann E, Zielen S, et al; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39(2):271-279
90. Kon OM, Sihra BS, Compton CH, et al. Randomised dose-ranging placebo controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998;352:1109-1113
91. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121(1):5-10
92. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133-1141
93. Jacobsen L, Valovirta E. How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma? Curr Opin Allergy Clin Immunol 2007;7(6):556-560
94. Bousquet PJ, Demoly P, Passalacqua G, et al. Immunotherapy: clinical trials-optimal trial and clinical outcomes. Curr Opin Allergy Clin Immunol 2007;7(6):561-566